ArticleScientific reports2025
The epiMelanoma test enables plasma-based detection of melanoma and prediction of immunotherapy response.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Radiomics: Current Applications and Future Directions.MedComm · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMelanoma is one of the most serious skin cancers worldwide, often progressing without obvious symptoms. Early detection is crucial to enable timely intervention, reducing morbidity and mortality. However, no standardized high-throughput test exists for non-invasive melanoma detection.
methodsThis diagnostic study aimed to develop and validate a high-throughput targeted DNA methylation-based test for detecting melanoma in cell-free DNA (cfDNA) from plasma and predicting response to immune checkpoint inhibitors (ICIs). A multiplexed next-generation sequencing assay targeting these five melanoma-specific DNA regions, named epiMelanoma, was developed and tested on a clinical cohort of 199 participants, including 121 melanoma patients (stages I-IV) from oncology clinics and 78 healthy donors sourced from biorepositories. Plasma cfDNA was collected from 187 participants, and biopsies from 35 patients.
resultsHere we show that epiMelanoma shows high classification accuracy in both biopsies and plasma cfDNA. First, four DNA regions categorically methylated across diverse cancers, including melanoma, but unmethylated in other tissues, were identified using TCGA and GEO datasets (n = 160), showing high classification accuracy (AUC = 0.9987, sensitivity 98.67%, specificity 100%). A fifth melanoma-specific region was discovered (cg04652957, sensitivity 100%, specificity 90.91%) and validated in 5479 samples. In clinical samples, sensitivity for early- and late-stage melanoma was 27% and 60%, respectively, with high specificity (98.15%). Sensitivity in biopsies exceeded 90%. Furthermore, a significant correlation was observed between the methylation signature and response to ICIs (p = 0.012), with lower M-scores associated with improved overall survival (log-rank p = 0.001, Kaplan-Meier).
conclusionsThe epiMelanoma assay represents a promising non-invasive tool for early melanoma detection and personalized treatment, by enabling timely intervention and identifying patients most likely to benefit from immunotherapy, and therefore, potentially improving patient outcomes and reducing healthcare burdens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.